Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ard.2003.020313v1
63/8/931    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pincus, T
Right arrow Articles by Fort, J G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pincus, T
Right arrow Articles by Fort, J G
Annals of the Rheumatic Diseases 2004;63:931-939
© 2004 by BMJ Publishing Group Ltd & European League Against Rheumatism


EXTENDED REPORT

Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis

T Pincus 1, G Koch 2, H Lei 3, B Mangal 3, T Sokka 1,4, R Moskowitz 5, F Wolfe 6, A Gibofsky 7, L Simon 8, S Zlotnick 3, J G Fort 3

1 Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
2 Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
3 Pfizer Corporation, USA
4 Department of Medicine, Jyvaskyla Central Hospital, Jyvaskyla, Finland
5 Division of Rheumatology, Case-Western University, Cleveland, OH 44106, USA
6 Wichita Arthritis Center, University of Kansas School of Medicine, 1035 North Emporia, Suite 230, Wichita, KS 67214, USA
7 Hospital for Special Surgery – Weill Medical College of Cornell University, New York, NY, USA
8 Department of Medicine, Harvard University, Boston, MA 02115, USA

Correspondence to:
Correspondence to:
Professor T Pincus
Division of Rheumatology and Immunology, Vanderbilt University School of Medicine, 203 Oxford House, Box 5, Nashville, TN 37232–4500, USA; t.pincus{at}vanderbilt.edu

Background: Acetaminophen (paracetamol) is recommended as the initial pharmacological treatment for knee or hip osteoarthritis. However, survey and clinical trial data indicate greater efficacy for non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 specific inhibitors.

Design: Two randomised, double blind, placebo controlled, crossover multicentre clinical trials, Patient Preference for Placebo, Acetaminophen or Celecoxib Efficacy Studies (PACES).

Patients: Osteoarthritis of knee or hip.

Intervention: "Wash out" of treatment; randomisation; 6 weeks of celecoxib 200 mg/day, acetaminophen 1000 mg four times a day, or placebo; second "wash out;" crossover to 6 weeks of second treatment.

Measurements: Western Ontario McMaster Osteoarthritis Index (WOMAC), visual analogue pain scale, patient preference between two treatments.

Results: Celecoxib was more efficacious than acetaminophen in both periods in both studies; WOMAC and pain scale scores differed at p<0.05 in period II and both periods combined of PACES-a and in periods I and II and both periods combined in PACES-b, but not in period I of PACES-a. Acetaminophen was more efficacious than placebo, generally p<0.05 in PACES-b, and >0.05 in PACES-a. Patient preferences were 53% celecoxib v 24% acetaminophen in PACES-a (p<0.001) and 50% v 32% in PACES-b (p = 0.009); 37% acetaminophen v 28% placebo in PACES-a (p = 0.340) and 48% v 24% in PACES-b (p = 0.007). No clinically or statistically significant differences were seen in adverse events or tolerability among the three treatment groups.

Conclusions: Greater efficacy was seen for celecoxib v acetaminophen v placebo, while adverse events and tolerability were similar. Variation in results and statistical significance in the two different trials are of interest.


Abbreviations: MDHAQ, Multidimensional Health Assessment Questionnaire; NSAIDs, non-steroidal anti-inflammatory drugs; SF-36, Short Form-36; WOMAC, Western Ontario McMaster Osteoarthritis Index

Keywords: celecoxib; osteoarthritis; acetaminophen; placebo; WOMAC; pain visual analogue scale; paracetamol




This article has been cited by other articles:


Home page
Ann Rheum DisHome page
P A Scott, G H Kingsley, C M Smith, E H Choy, and D L Scott
Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials
Ann Rheum Dis, October 1, 2007; 66(10): 1296 - 1304.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
E. Rahme and H. Nedjar
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study
Rheumatology, March 1, 2007; 46(3): 435 - 438.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
F P Luyten, P Geusens, M Malaise, L De Clerck, R Westhovens, F Raeman, D Vander Mijnsbrugge, L Mathy, J P Hauzeur, F De Keyser, et al.
A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip
Ann Rheum Dis, January 1, 2007; 66(1): 99 - 106.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
Y Yazici and H Yazici
A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor {alpha} inhibitors
Ann Rheum Dis, January 1, 2007; 66(1): 124 - 127.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
M. J. Yelland, C. J. Nikles, N. McNairn, C. B. Del Mar, P. J. Schluter, and R. M. Brown
Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials
Rheumatology, January 1, 2007; 46(1): 135 - 140.
[Abstract] [Full Text] [PDF]


Home page
Evid. Based Med.Home page
R. Lehman
Evidently...
Evid. Based Med., February 1, 2005; 10(1): 8 - 8.
[Full Text] [PDF]


Home page
Evid. Based Med.Home page
Other articles noted
Evid. Based Med., February 1, 2005; 10(1): 31 - 32.
[Full Text] [PDF]


Home page
Ann Rheum DisHome page
L Denoeud, B Mazieres, C Payen-Champenois, and P Ravaud
First line treatment of knee osteoarthritis in outpatients in France: adherence to the EULAR 2000 recommendations and factors influencing adherence
Ann Rheum Dis, January 1, 2005; 64(1): 70 - 74.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
E Roddy, W Zhang, M Doherty, and M. Dougados
Home based exercise for osteoarthritis * Author's reply
Ann Rheum Dis, January 1, 2005; 64(1): 170 - 171.
[Full Text] [PDF]


Home page
Ann Rheum DisHome page
R Neame, W Zhang, and M Doherty
A historic issue of the Annals: three papers examine paracetamol in osteoarthritis
Ann Rheum Dis, August 1, 2004; 63(8): 897 - 900.
[Full Text] [PDF]


Home page
Ann Rheum DisHome page
C Miceli-Richard, M Le Bars, N Schmidely, and M Dougados
Paracetamol in osteoarthritis of the knee
Ann Rheum Dis, August 1, 2004; 63(8): 923 - 930.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 BMJ Publishing Group Ltd & European League Against Rheumatism